Nasopharyngeal Carcinoma - 33 Studies Found
| Completed |
: Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma : Nasopharyngeal Carcinoma : 2025-08-03 : Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy. |
| COMPLETED |
: Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma : Nasopharyngeal Carcinoma : 2025-08-03 : On the first and second days of induction chemotherapy, lymph nodes were irradiated with 0.5Gy bid for 4 times. |
| COMPLETED |
: Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) : Nasopharyngeal Carcinoma : 2025-08-03 : Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14. |